Cargando…

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

BACKGROUND: Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurkmans, Daan P., Sassen, Sebastiaan D.T., de Joode, Karlijn, Putter, Lisanne, Basak, Edwin A., Wijkhuijs, Annemarie J.M., Joerger, Markus, Debets, Reno, Koch, Birgit C.P., Van der Leest, Cor H., Schreurs, Marco W.J., van der Veldt, Astrid A.M., Aerts, Joachim G.J.V., Mathijssen, Ron H.J., Koolen, Stijn L.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183294/ https://www.ncbi.nlm.nih.gov/pubmed/34088739 http://dx.doi.org/10.1136/jitc-2021-002344

Ejemplares similares

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

CD45RA(+)CCR7(−) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
por: Kunert, Andre, et al.
Publicado: (2019)

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis
por: ten Berge, Deirdre M.H.J., et al.
Publicado: (2019)

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
por: Agema, Bram C., et al.
Publicado: (2021)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition
por: de Joode, K., et al.
Publicado: (2021)

Preoperative mediastinal staging in patients with cT1‐3NxM0 non‐small cell lung cancer
por: Steunenberg, Bastiaan E., et al.
Publicado: (2020)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
por: Agema, Bram C., et al.
Publicado: (2020)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
por: Beije, Nick, et al.
Publicado: (2017)

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma
por: van der Leest, Cor, et al.
Publicado: (2018)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
por: Hurkmans, Daan P, et al.
Publicado: (2020)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

Improving the tolerability of osimertinib by identifying its toxic limit
por: Agema, Bram C., et al.
Publicado: (2022)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020)

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma
por: Kamminga, Nadia C.W., et al.
Publicado: (2022)

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
por: Lievense, Lysanne A., et al.
Publicado: (2022)

' Zorgen voor een ander is veel gemakkelijker dan zorgen voor jezelf'
por: Wijkhuijs, Jozien, et al.
Publicado: (2020)

'Ik ben een bedrijfsarts met een hart voor publieke gezondheid'
por: Wijkhuijs, Jozien, et al.
Publicado: (2021)

' Geruststelling en goede uitleg kan patiënten al erg helpen'
por: Wijkhuijs, Jozien, et al.
Publicado: (2021)

Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
por: Klopp-Schulze, Lena, et al.
Publicado: (2020)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
por: Veerman, G. D. Marijn, et al.
Publicado: (2020)

Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
por: Hou, Jun, et al.
Publicado: (2010)

Optical Detection of Preneoplastic Lesions of the Central Airways
por: van der Leest, C., et al.
Publicado: (2012)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
por: de Goeje, Pauline L., et al.
Publicado: (2018)

Curdlan, zymosan and a yeast-derived β-glucan reshape tumor-associated macrophages into producers of inflammatory chemo-attractants
por: de Graaff, Priscilla, et al.
Publicado: (2020)

The development of the ADO-SQ model to predict 1-year mortality in patients with COPD
por: Owusuaa, Catherine, et al.
Publicado: (2022)

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies
por: de Joode, K., et al.
Publicado: (2023)

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
por: van Eerden, Ruben A G, et al.
Publicado: (2020)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium
por: de Joode, Karlijn, et al.
Publicado: (2021)

Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial
por: Chalmers, James D., et al.
Publicado: (2018)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6n3u8iee988c6sc2e3lhap1hc1